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Edited by Beat ImhofAbstract Osteopontin is a multifunctional glycoprotein with
roles in immunomodulation, inﬂammatory response, tissue min-
eralization, and tissue remodeling, which are mediated primarily
through integrins. Transglutaminase 2 selectively cross-links
proteins by isopeptide bonding. Osteopontin is one of the sub-
strates of this enzyme and undergoes polymerization; however,
the biological meaning of this polymerization remains unknown.
Using recombinant osteopontin polymerized with puriﬁed trans-
glutaminase 2, we examined cell adhesion, spreading, focal con-
tact formation, and migration of SW480 or HUVE cells. All of
these cellular behaviors were dramatically enhanced with poly-
meric osteopontin. These enhancements of cellular functions
imply that polymerization might modulate physiological and
pathological functions of osteopontin.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Polymerization1. Introduction
Osteopontin is an acidic phosphorylated glycoprotein with
versatile functions, including roles in tissue remodeling, ﬁbro-
sis, mineralization, immunomodulation, and inﬂammation
[1,2]. The principal ways osteopontin aﬀects cellular behavior
is through interactions with integrins or CD44 [3]. Integrins
are heterodimeric cell surface glycoproteins that mediate cell
response to extracellular matrix proteins [4,5]. Osteopontin
contains the canonical integrin recognition sequence, argi-
nine–glycine–aspartic acid (RGD), which is recognized by six
integrins [2,6]. Two other integrins bind to a non-RGD
(SVVYGLR) sequence [7,8]. Transglutaminase 2 (EC
2.3.2.13) is a widely distributed intra- and extracellular cal-
cium-dependent enzyme that catalyzes polymerization of its
substrate proteins by creating isopeptide cross-links between
glutamine and lysine residues [9]. Osteopontin serves as one
of the substrates for this enzyme [10,11]. However, functions
of resultant polymeric osteopontin are still unknown exceptAbbreviations: BSA, bovine serum albumin; DMEM, Dulbecco’s
modiﬁed Eagle’s medium; PBS, phosphate buﬀered saline; FBS, fetal
bovine serum
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properties [12]. Recently, polymeric osteopontin was found
in vivo in rat bone [11] and in calciﬁed arteries of matrix Gla
protein deﬁcient mice [13]. The presence of polymeric osteo-
pontin suggests possible roles in normal and pathological tis-
sues. Here, we demonstrated functional signiﬁcance of the
polymerization. Integrin-mediated cell adhesion, spreading
and migration were all enhanced.2. Materials and methods
2.1. Cells, antibodies, and reagents
The human colon carcinoma cell line SW480 was obtained from
American Type Culture Collection. Human umbilical vein endothelial
(HUVE) cells were purchased from Cambrex (Walkersville, MD).
SW480 cells were used for cell adhesion and migration assays because
we have previously characterized the cells for adhesion to several forms
of osteopontin. HUVEC cells, which readily extend cytoplasm on a
substrate, were used for observation of cell spreading and focal contact
formation. Anti-human integrin monoclonal antibodies, anti-a1
(FB12), a2 (P1E6), a4 (P1H4), a5b1 (JBS5), a6 (NKI-GoH3), avb3
(LM609), and b1 (P5D2) were purchased from Chemicon (Temecula,
CA); anti-a3 (P1B5) and RGD peptide were purchased from Invitro-
gen (Grand Island, NY). An antibody against avb5 (P1F6) was from
Dr. Dean Sheppard (UCSF, San Francisco, CA). Anti-human osteo-
pontin polyclonal antibody was obtained from IBL (Takasaki, Japan).
Anti-CD151 monoclonal antibody, 8C3, was from Dr. Kiyotoshi Sek-
iguchi (Osaka University, Osaka, Japan). Fluorescent or HRP conju-
gated secondary antibodies were from BD Pharmingen (San Diego,
CA), Zymed (San Francisco, CA) and Invitrogen. Mouse anti-human
phosphotyrosine monoclonal antibody was from Santa Cruz Biotech-
nology (Santa Cruz, CA). Transglutaminase 2 was puriﬁed and pro-
vided by Dr. Yuji Saito (Tokyo Institute of Technology, Yokohama,
Japan) [14]. Recombinant human osteopontin with or without the
RAA mutation was produced as previously described [6,7].
2.2. Polymerization of osteopontin by transglutaminase 2
Recombinant human osteopontin (50 lg/ml) was incubated with
transglutaminase 2 at concentrations of 0–200 lg/ml in the reaction
buﬀer [5 mM CaCl2, 1 mM DTT, and 50 mM Tris–HCl (pH 7.5)] at
37 C for 2 h. The resultant osteopontin was conﬁrmed by Western
blotting to have formed a polymer. Polymerized osteopontin generated
with 100 lg/ml transglutaminase 2 was used in the following experi-
ments. Transglutaminase 2 was not removed from the polymerized
osteopontin preparation.
2.3. Cell adhesion and spreading assay
The cell adhesion assay was performed essentially as described [15].
Flat-bottom 96-well microtiter plates (Nunc Inc., Naperville, IL) were
coated with 100 ll of monomeric or polymeric osteopontin in phos-
phate buﬀered saline (PBS) at 4 C overnight. After wells were blocked
with 1% bovine serum albumin (BSA) in Dulbecco’s modiﬁed Eagle’s
medium (DMEM), a total of 5 · 104 cells in 100 ll of DMEM were
added to each well then incubated for 30 min at 37 C. The adhered
cells were ﬁxed and stained with 0.5% crystal violet for quantiﬁcation.
The optical density of cells adhered to 1% BSA was subtracted in eachblished by Elsevier B.V. All rights reserved.
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(0.1 mg/ml), cells were pre-incubated on ice for 15 min. The spreading
assay with HUVE cells was performed using the plates coated as de-
scribed above and assessed by counting cells with extended and trans-
parent cytoplasm after incubation for 30 min at 37 C.
2.4. Cell migration assay
The bottom sides of polycarbonate membranes with 8-lm pores
(Transwell, Corning, NY) were coated with 15 ll of 10 lg/ml mono-
meric or polymeric osteopontin, or 20 lg/ml of transglutaminase 2.
1 · 105 cells were added to the top of each chamber, then allowed to
migrate to the lower chambers containing DMEM with 1% fetal
bovine serum (FBS) for 24 h at 37 C in a humidiﬁed atmosphere with
5% CO2. Migrated cells on the bottom side of the membrane were
stained with crystal violet for counting.
2.5. Confocal microscopy
Chamber slides (BD, Franklin Lakes, NJ) were coated with 1.0 lg/
ml of monomeric or polymeric osteopontin overnight at 4 C. 1 · 105
cells were added to each chamber and incubated for 30 min at 37 C.
Cells were ﬁxed and permeabilized, then anti-human phosphotyrosine
mouse monoclonal antibody was added and incubated for 1 h followed
by incubation with Alexa Fluor 555 anti-mouse IgG. Actin ﬁlaments
were stained with Alexa Fluor 488 phalloidin. Confocal microscopy
analyses were performed with a LSM5 Pascal-V3.2 (Carl Zeiss Japan,
Tokyo, Japan).Fig. 2. Adhesion of SW480 cells to monomeric and polymeric
osteopontin. 5 · 104 cells in DMEM were plated on wells coated with
monomeric (open square) or polymeric (closed square) osteopontin, or3. Results
3.1. Transglutaminase 2 catalyzes osteopontin to form polymer
Immunoblotting with the anti-osteopontin polyclonal anti-
body showed dose-dependent multimerization from 10 to
200 lg/ml of transglutaminase 2, as manifested by the increase
in the smeared band with a molecular mass over 200 kDa and
a decrease in intensity of single bands less than 30 kDa corre-
sponding to monomeric recombinant osteopontin (Fig. 1A), of
which putative molecular weight was 34 kDa. Because the
intensity of the smeared bands of polymeric osteopontin was
much higher than the single sharp band of monomeric osteo-
pontin, the intensity appeared to be diﬀerent among the lanes,
although the same amount of proteins were loaded. Fig. 1B
shows that the puriﬁed transglutaminase 2 was not immunore-
active at all with anti-osteopontin antibody.Fig. 1. Dose-dependent polymerization of recombinant osteopontin
by transglutaminase 2. (A) Recombinant osteopontin was incubated
with or without transglutaminase 2 in the reaction buﬀer. 0.5 lg of the
resultant proteins was loaded into each lane of a 10% polyacrylamide
gel and probed with the anti-osteopontin polyclonal antibody.
Molecular mass of recombinant monomeric osteopontin that lacks
signal sequence corresponds to about 30 kDa. (B) 0.5 lg of the puriﬁed
transglutaminase 2 alone was run on a gel and probed with anti-
osteopontin antibody.3.2. Enhanced cell adhesion to polymeric osteopontin (Fig. 2)
SW480 cells adhered to either monomeric or polymeric oste-
opontin in a dose-dependent manner. However, adhesion to
polymeric osteopontin was enhanced at all concentrations
from 0.1 to 1.5 lg/ml. SW480 cells minimally adhered to trans-
glutaminase 2.
3.3. Coating eﬃciency of monomeric and polymeric osteopontin
The coating solutions were subjected to Western blotting
after the incubation to visualize unbound osteopontin
(Fig. 3A). By densitometry [16] of the blot, monomeric and
polymeric osteopontin decreased by about 78 % and 72 %,
respectively, presumably reﬂecting adsorption of the protein
to the wells (Fig. 3B). The enhanced adhesion of SW480 cells
to polymerized osteopontin was not due to diﬀerence in coat-
ing eﬃciency.
3.4. Cell adhesion to polymeric osteopontin is mediated by
integrins
The adhesion to monomeric osteopontin was completely
abrogated by a combination of anti-a5b1 and anti-avb5 inte-
grin (Fig. 4A) as previously reported [6]. However, the
enhanced adhesion to polymeric osteopontin was onlytransglutaminase 2 (open circle) at concentrations of 0.05–1.5 lg/ml.
Each plot represents the mean (±S.D.) of triplicate wells of three
repeated experiments. *P < 0.05, **P < 0.01 (polymeric vs. monomeric,
Student’s t-test).
Fig. 3. Coating eﬃciency of monomeric and polymeric osteopontin.
30 ll of coating solutions of monomeric and polymeric osteopontin
(10 lg/ml) before and after 24 h incubation was subjected to Western
blotting with anti-osteopontin polyclonal antibody. The density was
quantiﬁed by the ImageJ software and coating eﬃciency was calculated
as percent decreased after incubation.
Fig. 4. Integrin-mediated adhesion of SW480 cells to monomeric or polymeric osteopontin. SW480 cells were plated onto wells coated with 1.0 lg/ml
of monomeric (A) or polymeric (B) osteopontin in the presence or absence of integrin-blocking antibodies or RGD peptide (250 lg/ml). Each bar
represents the mean (±S.D.) of triplicate wells of ﬁve repeated experiments.
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GRGDSP peptide or used OPN-RAA in which the RGD se-
quence was mutated to RAA. The peptide treatment com-
pletely abrogated cell adhesion of SW480 to monomeric
osteopontin but incompletely for polymeric osteopontin.
SW480 cells did not adhere to monomeric OPN-RAA but
did to the polymeric OPN-RAA. These RGD independent
adhesions to polymeric osteopontin, however, were completely
abrogated by combination of anti-avb5 and b1 blocking anti-
bodies.
3.5. Integrin a3b1 is a receptor for polymeric osteopontin
As presented in Fig. 5A, the integrin subunits a1, a2, a3, a5,
and a6 were expressed on SW480 cells. Therefore, with a com-
bination of antibodies against these subunits along with anti-
avb5 and a5b1, we examined which b1-integrin(s) might be
implicated in the adhesion. Anti-a3 substantially inhibited this
residual adhesion, whereas anti-a1, a2 and a6 had little or no
eﬀects (Fig. 5B). Further, combinations including anti-a3
inhibited residual adhesion, whereas anti-a1, -a2 or a6 made
little or no contribution (Fig. 5C). A monoclonal antibodyFig. 5. Inhibition of SW480 cell adhesion to polymeric osteopontin by combin
cells was analyzed by ﬂow cytometry. Filled histogram indicates control, uns
a6 in combination with anti-a5b1 and avb5. (C) The adhesion was blocked
functional. (D) Inhibition eﬀects of blockade for integrin a3b1, anti-CD15
adhesion was represented as percent of control. The adhesion in the presence o
(±S.D.) of triplicate wells.against tetraspanin CD151 can inhibit the function of a3b1
by disrupting a complex of a3b1 with CD151 [17]. Addition
of the anti-CD151 antibody completely blocked the adhesion
to polymeric osteopontin (Fig. 5D). These results indicate that
integrin a3b1 expressed on SW480 cells is the principal integrin
responsible for RGD-independent adhesion to polymeric oste-
opontin.
3.6. Enhanced spreading and focal contact formation of HUVE
cells on polymeric osteopontin
HUVE cells were well spread on polymeric osteopontin
within 30 min, while the majority of the cells on monomeric
osteopontin remained round (Fig. 6A). Approximately 50%
of cells had spread on polymeric osteopontin, while less than
10% of cells had spread on monomeric osteopontin
(Fig. 6B). Staining of HUVE cells with ﬂuorescein-labeled
anti-phosphorylated tyrosine and phalloidin showed that
HUVE cells plated on polymeric osteopontin formed focal
contacts, while HUVE cells on monomeric osteopontin did
not (Fig. 6C). Accumulation of phosphorylated tyrosine could
be seen at the margin of the spread cells on polymeric osteo-ations of integrin antibodies. (A) Expression of b1-integrins on SW480
tained cells. (B) The adhesion was blocked by either anti-a1, a2, a3, or
by a combination of antibodies that left only one of a1, a2, a3, or a6
1. The combinations of antibodies are shown under the ﬁgure. The
f anti-avb5 and a5b1 was taken as 100%. Each bar represents the mean
Fig. 6. Spreading and focal contact formation of HUVE cells on monomeric and polymeric osteopontin. HUVE cells in serum-free DMEM were
plated on 96-well plates coated with 1.0 lg/ml monomeric or polymeric osteopontin at a density of 5 · 103 cells per well. (A) Phase-contrast
microscopy of the HUVE cells. (B) Spread cells were scored for 500 cells. Each bar represents mean (±S.D.) of three counted areas. For confocal
microscopic observation, cells were double-stained with anti-phosphotyrosine followed by Alexa Fluor 555 goat anti-mouse IgG (red), and Alexa
Fluor 488 phalloidin (green) for actin ﬁlaments. (C) Stained cells on monomeric or polymeric osteopontin. (D) Magniﬁed view of cells on polymeric
osteopontin showing the location of phosphorylated tyrosine and actin ﬁlaments. 20-lm scale bars are indicated within the panels.
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ﬁbers.
3.7. Enhanced transmigration of SW480 cells to polymeric
osteopontin
Fig. 7A shows stained cells that had migrated onto the bot-
tom of membranes coated with monomeric or polymeric oste-
opontin. Quantitation of these results is shown in Fig. 7B.
Migration on monomeric osteopontin was completely and on
polymeric osteopontin was partially blocked by a combination
of anti-a5b1 and avb5 antibodies. Transglutaminase 2 did notFig. 7. Increased transmigration of SW480 cells to polymeric osteo-
pontin and its inhibition by anti-integrin antibodies. (A) Microscopic
view of stained cells transmigrated onto the bottom of the membrane
without any blockade. (B) Eﬀects of integrin-blocking antibodies, anti-
a5b1, and -avb5. Cells migrated in the presence or absence of the
blocking antibodies (open column, antibody (–); gray column, anti-
a5b1 and avb5) were counted for three microscopic areas. Each bar
represents mean (±S.D.) of the areas of the three repeated experiments.induce migration at the concentrarion present in the polymeric
osteopontin preparation at all.4. Discussion
This is the ﬁrst report that directly shows biological func-
tions of polymerized osteopontin. Previous studies have shown
polymerized osteopontin as a substrate for transglutaminase 2
in vitro [10,12,18] and in vivo [11,13,19]. However, very little is
known about the functional signiﬁcance of this post-transla-
tional modiﬁcation. In the present study, we have shown
in vitro with chemically polymeric recombinant osteopontin a
dramatically enhanced capability for cell adhesion, migration,
and spreading, which were mediated by integrins.
Polymerization might enhance interactions with integrins by
concentrating ligand-binding sites, thereby enhancing integrin
clustering. In fact, we observed that at high concentration of
monomeric and polymeric osteopontin (10 or 20 lg/ml), the
diﬀerence of adhesion of SW480 cells to these substrates was
less obvious (data not shown). However, in addition to
enhancing interactions with previously described integrin
receptors for osteopontin, polymerization results in new inter-
actions with the integrins a3b1. Because osteopontin changes
conformation upon polymerization [12] and is a highly ﬂexible
molecule [20,21], polymerization might expose a cryptic epi-
tope recognized by a3b1 for induced new recognition sites.
A high molecular mass band on a polyvinylidene ﬂuoride
(PVDF) membrane from rat bone, immunoreactive with
anti-osteopontin, was shown to contain 60% osteopontin
[22]. Immunoblotting of calciﬁed aorta from matrix Gla
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in smeared band with high molecular mass [13] like our in vitro
polymerization. In the aorta, macrophages were present in
direct contact with the polymerized osteopontin [13]. This re-
cent work demonstrated that osteopontin is polymeric in vivo
thus ensured that our chemically polymerized osteopontin is
not restricted to function in vitro. It also suggests that poly-
meric osteopontin aﬀects cellular functions.
The dramatic enhancement of biological activity of osteo-
pontin upon polymerization mediated by integrins sheds light
on the mechanism by which transglutaminase 2 plays a role in
cell–matrix interaction and suggests a new role for post-trans-
lational modiﬁcation in the regulation of osteopontin function.
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